Flagship Ventures Fund V General Partner Llc - Net Worth and Insider Trading

Flagship Ventures Fund V General Partner Llc Net Worth

The estimated net worth of Flagship Ventures Fund V General Partner Llc is at least $2 Million dollars as of 2024-11-13. Flagship Ventures Fund V General Partner Llc is the 10% Owner of Omega Therapeutics Inc and owns about 2,197,059 shares of Omega Therapeutics Inc (OMGA) stock worth over $2 Million. Flagship Ventures Fund V General Partner Llc is also the 10% Owner of Evelo Biosciences Inc and owns about 911,670 shares of Evelo Biosciences Inc (EVLO) stock worth over $410. Details can be seen in Flagship Ventures Fund V General Partner Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Flagship Ventures Fund V General Partner Llc has not made any transactions after 2021-08-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Flagship Ventures Fund V General Partner Llc

To

Flagship Ventures Fund V General Partner Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Flagship Ventures Fund V General Partner Llc owns 9 companies in total, including Foghorn Therapeutics Inc (FHTX) , Codiak BioSciences Inc (CDAKQ) , and Kaleido Biosciences Inc (KLDO) among others .

Click here to see the complete history of Flagship Ventures Fund V General Partner Llc’s form 4 insider trades.

Insider Ownership Summary of Flagship Ventures Fund V General Partner Llc

Ticker Comapny Transaction Date Type of Owner
FHTX Foghorn Therapeutics Inc 2020-10-22 10 percent owner
CDAKQ Codiak BioSciences Inc 2020-10-13 10 percent owner
KLDO Kaleido Biosciences Inc 2019-02-27 director & 10 percent owner
LIMIT LIMIT 2018-05-11 10 percent owner
LIMIT LIMIT 2017-12-07 10 percent owner
LIMIT LIMIT 2021-03-19 10 percent owner
LIMIT LIMIT 2021-02-03 10 percent owner
LIMIT LIMIT 2020-12-03 10 percent owner
LIMIT LIMIT 2021-08-03 10 percent owner

Flagship Ventures Fund V General Partner Llc Latest Holdings Summary

Flagship Ventures Fund V General Partner Llc currently owns a total of 2 stocks. Among these stocks, Flagship Ventures Fund V General Partner Llc owns 2,197,059 shares of Omega Therapeutics Inc (OMGA) as of August 3, 2021, with a value of $2 Million and a weighting of 99.98%. Flagship Ventures Fund V General Partner Llc also owns 911,670 shares of Evelo Biosciences Inc (EVLO) as of May 11, 2018, with a value of $410 and a weighting of 0.02%.

Latest Holdings of Flagship Ventures Fund V General Partner Llc

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
OMGA Omega Therapeutics Inc 2021-08-03 2,197,059 1.13 2,482,677
EVLO Evelo Biosciences Inc 2018-05-11 911,670 0.00 410

Holding Weightings of Flagship Ventures Fund V General Partner Llc


Flagship Ventures Fund V General Partner Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Flagship Ventures Fund V General Partner Llc has made a total of 1 transactions in Omega Therapeutics Inc (OMGA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Omega Therapeutics Inc is the acquisition of 1,176,469 shares on August 3, 2021, which cost Flagship Ventures Fund V General Partner Llc around $20 Million.

According to the SEC Form 4 filings, Flagship Ventures Fund V General Partner Llc has made a total of 0 transactions in Evelo Biosciences Inc (EVLO) over the past 5 years. The most-recent trade in Evelo Biosciences Inc is the acquisition of 14,063 shares on May 11, 2018, which cost Flagship Ventures Fund V General Partner Llc around $5 Million.

Insider Trading History of Flagship Ventures Fund V General Partner Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Flagship Ventures Fund V General Partner Llc Trading Performance

GuruFocus tracks the stock performance after each of Flagship Ventures Fund V General Partner Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Flagship Ventures Fund V General Partner Llc is 21.03%. GuruFocus also compares Flagship Ventures Fund V General Partner Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Flagship Ventures Fund V General Partner Llc within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Flagship Ventures Fund V General Partner Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Flagship Ventures Fund V General Partner Llc

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 4.02 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 1.75 LIMIT LIMIT LIMIT LIMIT LIMIT

Flagship Ventures Fund V General Partner Llc Ownership Network

Ownership Network List of Flagship Ventures Fund V General Partner Llc

No Data

Ownership Network Relation of Flagship Ventures Fund V General Partner Llc

Insider Network Chart

Flagship Ventures Fund V General Partner Llc Owned Company Details

What does Foghorn Therapeutics Inc do?

Who are the key executives at Foghorn Therapeutics Inc?

Flagship Ventures Fund V General Partner Llc is the 10 percent owner of Foghorn Therapeutics Inc. Other key executives at Foghorn Therapeutics Inc include Chief People Officer Carlos Costa , See Remarks Steven F. Bellon , and Chief Strategy/Bus Ops Officer Fanny Cavalie .

Foghorn Therapeutics Inc (FHTX) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund V General Partner Llc made no insider transaction in Foghorn Therapeutics Inc (FHTX). Other recent insider transactions involving Foghorn Therapeutics Inc (FHTX) include a net sale of 58,859 shares made by Carlos Costa , a net sale of 311,297 shares made by Samuel Agresta , and a net sale of 20,000 shares made by Steven F. Bellon .

In summary, during the past 3 months, insiders sold 78,859 shares of Foghorn Therapeutics Inc (FHTX) in total and bought 0 shares, with a net sale of 78,859 shares. During the past 18 months, 401,156 shares of Foghorn Therapeutics Inc (FHTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 401,156 shares.

Foghorn Therapeutics Inc (FHTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Foghorn Therapeutics Inc Insider Transactions

No Available Data

Flagship Ventures Fund V General Partner Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Flagship Ventures Fund V General Partner Llc. You might contact Flagship Ventures Fund V General Partner Llc via mailing address: 55 Cambridge Parkway, Suite 800e, Cambridge Ma 02142.